Navigation Links
LocumTenens.com Names Kevin Weeks as Vice President, Marketing
Date:4/2/2009
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
LocumTenens.com Names Kevin Weeks as Vice President, Marketing
LocumTenens.com Names Kevin Weeks as Vice President, Marketing
(Date:11/25/2009)...ERSPRING,Md.,Nov.25/PRNewswire-USNewswire/--Anarti...rDrugEvaluationandResearch,titled"ADifficultBalanc...eNov.26,2009issueofTheNewEnglandJournalofMedicine....20090824/FDALOGO ) ,, Inthearticle,Woodcockdisc...medicationforthosewhoneeditandmanagingtheriskspose...
(Date:11/25/2009)...s have found evidence of a statistically significa...patients whose estrogen receptor (ER)-positive tum...; at serine-118 (ER-alpha S118-P), according to a ...n the Journal of the National Cancer Institute . ...istant to tamoxifen. Preclinical studies have show...
(Date:11/25/2009)... Evaluation and treatment clinics to ...Woodstock (Vocus) November 25, 2009 -- Centegra He...ines and H1N1 vaccine shots at four Centegra Prima...ipment of vaccine has arrived. The clinics are at ...McHenry and will be open as follows: ,   ...
(Date:11/25/2009)...NGTON,Va.,Nov.25/PRNewswire-USNewswire/--TheAmeric...thCareFraudActof2009,"S.2128,whichisdesignedtosubs...tfraudinMedicare.ThebillwasintroducedbySen.GeorgeL...lprovisionstheAmericanAssociationforHomecareoutlin...ationproposedtoCongressinFebruary.Thoseprovisionsi...
(Date:11/25/2009)...ks placed under the skin kill tumor cells, study f...ews) -- A cancer vaccine delivered in a fingernail...a new study reports. , The method uses polymer ...d with tumor-specific antigens and implanted under... tumors. The Harvard University scientists who dev...
Breaking Medicine News(10 mins):Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2
...tial financial income and the c...ime is a precious commodity, and so,people are inc... their,time, especially when it comes to financial...rgest online and catalog companies catering,exclus...
...ior Management Team, NASHVILLE, Tenn., May 20 Em...nue cycle management and clinical communication,so...as been named Senior,Vice President of Corporate S...ntly, Ms. Paramore was a,Partner with Commonwealth...
...fits of,lipid-modifying drugs, current management ...n a new supplement to The Journal of Family,Practi... in aggressive,lipid lowering" reviews the evidenc... patients., "High-dose statin therapy: Benefits a...
...in key organs , , TUESDAY, May 20 (HealthD...lso protect against adenovirus, which causes upper...uses that causes the common cold. , Currently, the...hing that needs to be done before new drugs can be...
...oomers,have challenged many industries to replace ...the multi-generational workforce is challenging,co...s to engage employees,and to define a new type of ...long,term strategies through dynamic case study pr...
...s with latent tuberculosis (TB), who are infected ...t it in less than half the time and at a lower cos...o researchers who conducted a multi-center, random... We found that using a therapy of four months of R...
Other Medicine News:Health News:Lucrative Sales Opportunities Abound With Melaleuca, The Wellness Company(R) 2Health News:Emdeon Business Services Names Miriam Paramore Senior Vice President of Corporate Strategy 2Health News:Reductions in CV Morbidity and Mortality are Achievable! 2Health News:Smallpox Drug May Protect Against Common Cold 2Health News:Fortune 500s to Convene in Florida, Sharing Insights & Best Practices for Developing Tomorrow's Leaders 2Health News:Rifampin: Latent TB treatment saves time money and lives 2
(Date:11/25/2009)...TON,N.J.,Nov.25/PRNewswire-FirstCall/--Pharmasset,...mpanycommittedtodiscovering,developingandcommercia...ancialresultsforthefiscalyearendedSeptember30,2009...h,cashequivalentsandshortterminvestments. ,, P..., Phase2bTrial ,, InlateNovember2009,anind...
(Date:11/25/2009)...WATER,N.J.,Nov.25/PRNewswire/--TheFDAgrantedtradit...,anon-nucleosidereversetranscriptaseinhibitor(NNRT...useintreatment-experiencedadultswhoareexperiencing...andotherantiretroviral(ARV)agents.Thetraditionalap...nasDUET-1andDUET-2.INTELENCEiscurrentlymarketedint...
(Date:11/25/2009)...GRIDGE,N.J.,Nov.25/PRNewswire/--RegadoBiosciences,...romboticaptamerswithactivecontrolagents,announcedt...atthePiperJaffray21stAnnualHealthCareConferenceatt...tationwillbegivenat1:10pm(EST)onTuesday,December1a...mphasisontheleaddevelopmentprogram,theanticoagulan...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 6189 1Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 6189 2Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 6189 3Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 6189 4Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 6189 5Webcast Alert 3A Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA 6184 1Webcast Alert 3A Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA 6184 2Understanding mechanical properties of silicon nanowires paves way for nanodevices 14797 1Understanding mechanical properties of silicon nanowires paves way for nanodevices 14797 2
...erumo Heart, Inc. announced,today that they have r...g,Administration (FDA) to begin enrollment in the ...Bridge-to-Transplant (BTT) indication., (Logo: h...3LOGO ), (Photo: http://www.newscom.com/cgi-bin...President of Clinical Studies, Regulatory,Affairs ...
...9 Eisai Corporation of,North America, a wholly-ow...unced today that the Food and Drug Administration ...g Application (sNDA) for the short-term (up to,eig...ease (GERD) in,patients ages 12-16. Further, FDA h...eview in accordance with the Best Pharmaceuticals ...
Other Medicine Technology:DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial 2FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents 2
RIDASCREEN Anti-VZV IgM Assay
...ricella- Zoster Virus (VZV) IgG Enzyme- linked Imm...tion and quantitative determination of IgG antibod... may be used for the determination of immune statu...d to demonstrate seroconversion or a significant r...
...nzyme-Linked Immunosorbent Assay (ELISA) is intend...n of IgG antibody to VZV in human sera. Individua...n of immune status. Paired sera, acute and convale...r a significant rise in antibody level, as an aid ...
RIDASCREEN Anti-Mumps Virus IgM Assay
Medicine Products: